SCHEMBL13313254

SCHEMBL13313254

Oc1ccc(F)c2cncnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 12/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ MPI P34949 1/20 0.55
▸ RPS6KB1 P23443 6/20 0.38
▸ AKT1 P31749 1/20 0.34
▸ HSP90AA1 P07900 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ HTT P42858 2/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ METAP2 P50579 1/20 0.34
▸ METAP1 P53582 1/20 0.34
▸ HSP90AB1 P08238 1/20 0.34
▸ IDO1 P14902 1/20 0.34
▸ PSMB5 P28074 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ MITF O75030 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15741558 0.84 RPS6KB1 (0.35) KDM4EL3MBTL1MPIRPS6KB1AKT1
SCHEMBL30449241 0.84 RPS6KB1 (0.35) KDM4EL3MBTL1MPIRPS6KB1AKT1
SCHEMBL28176993 0.84 EP300 (0.39) KDM4EL3MBTL1MPIHSP90AA1LMNA
SCHEMBL3241243 0.77 KDM4E (0.55) KDM4EL3MBTL1MPIRPS6KB1HSP90AA1
SCHEMBL13271230 0.77 CD38 (0.33) KDM4EL3MBTL1MPIRPS6KB1AKT1
SCHEMBL13271033 0.77 HTT (0.55) KDM4EL3MBTL1MPIRPS6KB1HSP90AA1
SCHEMBL3232367 0.77 NQO2 (0.39) KDM4EL3MBTL1MPIHSP90AA1LMNA
SCHEMBL28215110 0.76 COMT (0.43) KDM4EL3MBTL1MPIRPS6KB1AKT1
SCHEMBL29638689 0.74 RPS6KB1 (0.60) RPS6KB1AKT1
SCHEMBL13313257 0.73 ERN1 (0.37) KDM4EL3MBTL1RPS6KB1AKT1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 — — US disclosed
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2010-06-24 — — US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 — — US disclosed
US-7692011-B2 8-hydroxy and 8-mercapto quinazolinones PRANA BIOTECHNOLOGY LIMITED (AU) 2010-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160346-A1 NEUROLOGICALLY ACTIVE COMPOUNDS ACHE, PSEN1, PSEN2 KDM4E 3329/4885L3MBTL1 2272/4885MPI 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback